What are medical devices (medtech) patents?
A medical device patent protects a novel, non-obvious and useful invention related to diagnosing, monitoring or treating patients, following the same core patentability standards as any other utility patent. Medical device patents often run in parallel with regulatory approval, FDA clearance in the US or CE marking under the EU Medical Device Regulation, and Europe excludes methods of medical treatment from patentability.
Same patentability test, two extra regulatory tracks running in parallel
A medical device patent is examined against the same novelty, non-obviousness and usefulness standard as any other utility patent. What makes medtech genuinely different is that patent prosecution almost never happens in isolation, it runs alongside a separate regulatory approval process that has its own timeline, its own requirements, and no formal coordination with the patent office. Missing that parallel track, treating patent strategy and regulatory strategy as sequential rather than concurrent, is one of the most common and costly planning mistakes in this space.
FDA classification and the CE marking equivalent
The FDA sorts devices into three risk-based classes, and the class determines the pathway: Class I and most Class II devices go through 510(k) clearance, showing substantial equivalence to an already-approved device, while Class III devices need a full PMA application with clinical evidence. Europe's CE marking under the Medical Device Regulation works differently but serves the same gatekeeping function, and it is worth being precise about how separate this is from patent protection: a granted patent doesn't authorize sale, and CE marking doesn't protect the invention from being copied. Both are independently required, and neither substitutes for the other.
Patent term extension: recovering time lost to regulatory review
Because regulatory approval can take years during which a patented device can't be commercially marketed, the Hatch-Waxman Act's Section 156 lets a patent term be extended, up to 5 years, capped at 14 years of protection following approval, specifically to recover some of that lost commercial runway. This isn't automatic: the patent must claim the actually-approved product or a method tied to its use or manufacture, with claim language that maps onto the FDA's approval designation, which is where extension requests are most often denied. Europe has a parallel mechanism, supplementary protection certificates, that achieves a similar goal through separate application.
What most people get wrong
The most common mistake is assuming FDA approval and patent protection are linked, they aren't. There's no such thing as an "FDA patent," and clearing FDA review says nothing about whether a competitor's product infringes an existing patent, or whether your own device is protected from being copied. A second mistake is treating device claims and software claims as one filing when a device has meaningful digital components; the mechanical claims and the software claims face different eligibility standards and are often stronger drafted, and sometimes filed, separately.
How Lightbringer handles this
Lightbringer's attorneys align patent filing milestones with regulatory timelines during strategy planning, rather than treating FDA or CE approval as a separate workstream the patent team finds out about later. For devices with digital or AI components, mechanical and software claims get evaluated against their respective eligibility standards from the start.
Related Lightbringer guide: MedTech patents — vertical guide
External sources: FDA: Medical devices · European Commission: Medical devices sector (EU MDR) · USPTO: Subject matter eligibility guidance
Frequently asked questions
A medical device patent protects a novel, non-obvious and useful invention related to diagnosing, monitoring or treating patients, following the same core patentability standards as any other utility patent. Medical device patents often face additional complexity from overlapping regulatory approval processes, FDA clearance in the US or CE marking under the EU Medical Device Regulation, running in parallel with patent prosecution, and Europe additionally excludes methods of medical treatment themselves from patentability.
Patenting a medical device follows the standard process, disclosure, prior art search, drafting and filing, but typically requires closer attention to both mechanical and, where applicable, software claims if the device includes digital components. Coordinating patent strategy with regulatory timelines, FDA in the US, CE marking and MHRA approval in Europe and the UK, is also common, since both processes can run in parallel.
Medtech intellectual property spans patents on device mechanisms, software controlling digital health features, and sometimes biotech-adjacent compositions, combined with regulatory considerations specific to healthcare products. Companies in this space frequently need patent counsel familiar with both IP law and medical device regulatory pathways.
Medtech patent strategy typically means filing on core device mechanisms early, layering in software and digital health claims where relevant, and timing filings to align with regulatory milestones, FDA in the US, CE marking in Europe, rather than treating patent and regulatory strategy as separate tracks. Budget and development stage both shape how aggressively a medtech startup should file.
Medical device IP protection often combines patents on the core device with trade secret protection for manufacturing processes and trademark protection for the product brand. Regulatory data exclusivity, a separate protection tied to approval by regulators like the FDA or EMA, can also provide additional competitive runway alongside patent protection.
There's no such thing as an "FDA patent" specifically; FDA approval and patent protection are separate processes that often run in parallel, with patent protection covering the invention itself and FDA clearance governing whether it can legally be marketed. Some regulatory pathways create specific legal links between patent status and approval timing, like Hatch-Waxman for drugs in the US, or supplementary protection certificates in Europe that extend pharmaceutical patent term to compensate for approval delays.
Medical device regulatory IP refers to the intersection of patent protection and regulatory exclusivity periods granted by bodies like the FDA or EMA, which can extend a product's competitive protection beyond the patent alone in some cases. Navigating both tracks together is a specialised area combining patent and regulatory counsel.
CE marking is a regulatory conformity requirement for selling medical devices in the European market, separate from and unrelated to patent protection, which is a distinct legal right obtained through the EPO or national patent offices. A device typically needs both patent protection and CE marking to be both protected and legally saleable in Europe.
A digital health patent protects software-based healthcare technology, such as remote monitoring algorithms or diagnostic software, and faces the same eligibility considerations as other software patents (Section 101 in the US, the technical-character requirement in Europe). Claims need to describe a specific technical improvement rather than a general digital health concept to survive examination.
A medical AI patent protects a specific, novel technical method for applying AI to a healthcare problem, such as a diagnostic algorithm with a defined technical mechanism, rather than the general concept of AI-assisted diagnosis. As with other AI patents, specificity in the technical claim is what determines patentability.
A biotech patent protects novel biological inventions such as engineered organisms, specific therapeutic compounds, or biological processes, subject to additional restrictions on patenting naturally occurring substances in their unmodified form. Biotech patent claims require particularly careful drafting given the field's unique eligibility rules around natural phenomena.
For a medtech startup, IP strategy typically means filing early on core device or software innovations, budgeting for the reality that medtech patents often take longer to prosecute due to technical complexity, and aligning patent milestones with regulatory approval timelines in each target market. Given the capital intensity of medtech development, a clear, prioritised filing plan matters more here than in most other sectors.
Transform patents into momentum
See exactly what filing costs before you commit. No invoice shock. No budget-season surprises.